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ABSTRACT 1 
Introduction: 2 
Intrauterine growth restriction (IUGR) and preeclampsia (PE) are pregnancy disorders characterized 3 
by placental insufficiency with oxygen/nutrient restriction and oxidative stress, all influencing 4 
mitochondria functionality and number. Moreover, IUGR and PE fetuses are predisposed to 5 
diseases later in life, and this might occur through epigenetic alterations. 6 
Here we analyze content and methylation of mitochondrial DNA (mtDNA), for the first time in 7 
IUGR and PE singleton fetuses, to identify possible alterations in mtDNA levels and/or epigenetic 8 
control of mitochondrial loci relevant to replication (D-loop) and functionality (mt-TF/RNR1: 9 
protein synthesis, mt-CO1: respiratory chain complex). 10 
Methods: 11 
We studied 35 term and 8 preterm control, 31 IUGR, 17 PE/IUGR and 17 PE human singleton 12 
pregnancies with elective cesarean delivery. Fetal cord blood was collected and evaluated for 13 
biochemical parameters. Extracted DNA was subjected to Real-time PCR to assess mtDNA content 14 
and analyzed for D-loop, mt-TF/RNR1 and mt-CO1 methylation by bisulfite conversion and 15 
pyrosequencing. 16 
Results: 17 
mtDNA levels were increased in all pathologic groups compared to controls. Mitochondrial loci 18 
showed very low methylation levels in all samples; D-loop methylation was further decreased in the 19 
most severe cases and associated to umbilical vein pO2. mt-CO1 methylation levels inversely 20 
correlated to mtDNA content. 21 
Discussion: 22 
Increased mtDNA levels in IUGR, PE/IUGR and PE cord blood may denote a fetal response to 23 
placental insufficiency. Hypomethylation of D-loop, mt-TF/RNR1 and mt-CO1 loci confirms their 24 
relevance in pregnancy. 25 
26 
 3
ABBREVIATIONS 1 
IUGR: intrauterine growth restriction 2 
PE: preeclampsia 3 
mtDNA: mitochondrial DNA 4 
CO1: Cytochrome C Oxidase I 5 
TF/RNR1: tRNA Phenylalanine / 12S RNA 6 
BMI: body mass index 7 
pO2: oxygen partial pressure 8 
9 
 4
INTRODUCTION 1 
Intrauterine growth restriction (IUGR) and preeclampsia (PE) are pregnancy disorders characterized 2 
by defective placental functions, leading to impaired oxygen and nutrients transfer to the fetus [1-5], 3 
and increased oxidative stress and inflammation [6]. Adverse intrauterine conditions are known to 4 
have an impact also on adult health of newborns, predisposing them to later pathologies such as 5 
diabetes, cardiovascular diseases and allergic sensitization [7-9]. Reprogramming of fetal 6 
epigenome by intrauterine exposures can occur through methylation of DNA, affecting gene 7 
expression and activity without changes in DNA sequence. 8 
Mitochondria, as cell energy producers, have been recently investigated as potentially associated 9 
with the pathogenesis of placental insufficiency. The number of mitochondria is proportional to the 10 
energy requirements of the cells and can deviate from a “healthy range” in conditions of altered 11 
oxygen/nutrients availability or oxidative stress impairing mitochondrial functionality [10]. 12 
Mitochondria have their own DNA, coding for respiratory chain enzymes, which is distinct but in 13 
continuous cross-talk with the nuclear genome. The amount of mitochondrial DNA (mtDNA) is 14 
recognized as a measure of the mitochondrial content [11]. Changes in mitochondrial DNA levels 15 
have been consistently reported in placenta and maternal blood of pathologic pregnancies [12-17]. 16 
However, no data are available about mtDNA content in fetal blood of IUGR and PE singleton 17 
pregnancies. 18 
Mitochondrial DNA, in addition to nuclear DNA, is subjected to cytosine methylation by a 19 
mitochondrial-specific DNA methyltransferase [18]. Methylation makes DNA less accessible to 20 
replication and transcription, therefore it may potentially interfere with the expression of respiratory 21 
chain complexes, impacting on mitochondrial functionality. Few studies have been conducted on 22 
mtDNA methylation, focusing on degenerative diseases, cancer, aging and exposition to 23 
environmental pollutants [19-24]. 24 
 25 
 5
In this study, we investigated mitochondrial DNA in fetal cord blood of pregnancies affected by 1 
IUGR and/or PE. In particular, we evaluated whether alterations of mitochondrial content, reported 2 
for placentas and maternal blood, are also present in the fetus, and we analyzed the methylation 3 
levels of three mitochondrial genes in pathologic versus control fetuses to evaluate for a possible 4 
epigenetic control of mitochondrial number and gene expression. D-loop, mt-CO1 and mt-TF/RNR1 5 
are mitochondrial loci relevant to mtDNA and mitochondrial functionality that have been already 6 
tested in methylation studies on other pathologies [19-24]. D-loop control region is involved in 7 
mtDNA replication, mt-TF/RNR1 locus contains two genes respectively constituting phenylalanine 8 
tRNA (TF) and 12S rRNA (RNR1), both needed for protein synthesis, whereas mt-CO1 encodes for 9 
Cytochrome C oxidase subunit 1, belonging to respiratory chain and thus involved in mitochondrial 10 
function. 11 
 12 
METHODS 13 
Population 14 
One hundred and eight pregnancies were studied: control pregnancies at term (n=35) and preterm 15 
(n=8), and pregnancies complicated by placental insufficiency (IUGR: n=31; PE/IUGR: n=17; PE: 16 
n=17). 17 
Only patients with singleton pregnancies undergoing elective Cesarean section were included in this 18 
study. Exclusion criteria for all groups were maternal drug or alcohol abuse, maternal or fetal 19 
infections, fetal abnormal karyotype or major malformations. All pregnant women were of 20 
Caucasian origin. 21 
Controls were term (> 37 weeks) or preterm (≤ 37 weeks) pregnancies with normal intrauterine 22 
growth and appropriate-for-gestational-age birth weight according to reference ranges for the Italian 23 
population [25]. Indications for Cesarean section were breech presentation, previous Cesarean 24 
delivery or maternal indications not influencing fetal growth. 25 
 6
IUGR fetuses were identified in utero, through longitudinal measurements indicating abdominal 1 
circumferences below the 10th percentile of age-related reference values and a shift from the 2 
reference growth curve greater than 40 centiles [26]. IUGR pregnancies were further classified 3 
according to umbilical artery pulsatility index, measured by Doppler velocimetry [27-29]. 4 
Preeclampsia was defined as blood pressure >140/90 mmHg in two measurements/24h and 5 
proteinuria >300mg/24h after the 20th week of pregnancy in a previously normotensive and 6 
nonproteinuric woman [30]. PE pregnancies were further divided in two subgroups, with disease 7 
onset before or after the 34th week of gestation. 8 
The study was approved by the Institutional Ethics Committee, and all pregnant patients gave their 9 
informed consent. 10 
 11 
Sampling 12 
Umbilical blood was collected from a doubly-clamped segment of the cord at the time of Cesarean 13 
section and stored at -20°C until analysis. 14 
Oxygenation and acid-base parameters of umbilical artery and vein blood were measured 15 
immediately after delivery using a GEM Premier 3000 portable system (Instrumentation 16 
Laboratory). 17 
 18 
mtDNA analysis 19 
Total DNA was extracted from cord blood samples using QIAamp DNA Blood Mini Kit (Qiagen; 20 
Valencia, CA, USA) and quantified by NanoDrop ND 1000 spectrophotometer (NanoDrop 21 
Technologies; Wilmington, DE, USA). 22 
 23 
mtDNA content was assessed in Real-time PCR experiments by normalizing the levels of a 24 
mitochondrial gene (Cytochrome B) to those of a single-copy nuclear gene (RNase P). For each 25 
gene, 30 ng of total DNA were analyzed in triplicate with TaqMan assays (Hs02596867_s1 and 26 
 7
4316849) on the 7500 Fast Real-Time PCR System (Applied Biosystems by ThermoFisher 1 
Scientific; Carlsbad, CA, USA). Cq values with standard deviation exceeding 0.25 were excluded 2 
and experiments repeated. The median inter-run coefficient of variation was 1.90%. For each 3 
sample, mtDNA level was calculated as 2-∆Cq, obtained after subtracting RNase P average Cq value 4 
to Cytochrome B average Cq value (∆Cq). 5 
 6 
mtDNA methylation analyses were performed in a subset of cord blood samples (24 term controls, 7 
6 preterm controls, 24 IUGR, 14 PE/IUGR and 9 PE). 8 
Total DNA samples (100-500 ng) were bisulfite-converted using EZ DNA Methylation-Direct Kit 9 
(Zymo Research Corporation; Irvine, CA, USA) and eluted in 30 µl of M-Elution buffer. 10 
Bisulfite-converted DNA (20-50 ng) was subjected to PCR of mitochondrial D-loop, TF/RNR1 and 11 
CO1 segments, in a final volume of 50 µl, with GoTaq Hot Start Polymerase (Promega; Madison, 12 
WI, USA) and specific primers (Supplementary Table). Cytosine methylation was quantified by 13 
pyrosequencing using primers described in Supplementary Table and PyroGold SQA Reagent Kit 14 
(Qiagen). Pyrosequencing also allowed to verify bisulfite conversion occurred properly: data from 15 
incompletely converted samples were excluded and experiments repeated. The methylation 16 
percentage at each CpG site was quantitatively analyzed by PyroMark ID instrument and software 17 
Q-CpG v.1.0.11 (both Qiagen). Methylation values represent the mean between at least two 18 
independent PCR and pyrosequencing experiments, with a standard deviation ≤3%. The median 19 
inter-run coefficient of variation was 8.08%. 20 
 21 
Real-time PCR and pyrosequencing runs were carried out in a blinded and randomized fashion. 22 
 23 
Statistical analysis 24 
Data distribution was evaluated with the Kolmogorov-Smirnov test. Maternal age and D-loop 25 
methylation levels, showing normal distribution, were compared between two groups using 26 
 8
independent-samples t-test, with applied correction when the equality of variances assumption was 1 
violated (Levene’s test). All other clinical and molecular data were analyzed by independent-2 
samples Mann-Whitney U test. Correlation between values was assessed using bivariate Pearson 3 
correlation and the r coefficient reported. Differences and correlations were considered statistically 4 
significant when p<0.05. No adjustments for multiple comparisons were made. 5 
Analyses were performed using the statistical package SPSS (IBM SPSS Statistics, v.23; Armonk, 6 
NY, USA). 7 
 8 
RESULTS 9 
 10 
Clinical data of the study population 11 
Maternal and fetal characteristics of cases and controls are compared in Table 1. 12 
As expected, PE women had higher pre-pregnancy BMI. All pathologic cases had lower gestational 13 
age, placental and fetal weight than term controls. However, gestational age of IUGR and PE 14 
fetuses was similar to the preterm control subgroup. 15 
 16 
mtDNA content 17 
No significant relationship was observed between mtDNA content and gestational age in control 18 
pregnancies. Moreover, there were no significant differences between term and preterm controls 19 
(Figure 1A). Based on these observations and given the small size of the preterm control group, we 20 
pooled the term and preterm controls for all subsequent comparisons. 21 
All cases presented a strong significant increase in mtDNA levels compared to controls (Figure 1B; 22 
IUGR p=0.000; PE/IUGR p=0.004; PE p=0.000). 23 
We further examined pathologic samples after classifying them for disease severity: IUGR (with or 24 
without PE) were divided in two subgroups with normal or altered pulsatility index, PE pregnancies 25 
with disease onset before or after the 34th week of gestation. As shown in Figure 2, mtDNA content 26 
 9
was significantly increased in all cases, independently from their severity, and no differences were 1 
observed within IUGR or PE groups. 2 
 3 
mtDNA methylation 4 
We then further analyzed mitochondrial DNA by evaluating, in a subset of cord blood samples, 5 
methylation levels of three mitochondrial segments, D-loop, CO1 and TF/RNR1, involved in 6 
mitochondrial replication and function. In this sample subset, clinical characteristics and the relative 7 
number of cases and controls were similar to the entire population. 8 
No significant relationship was observed between methylation levels and gestational age in control 9 
pregnancies, nor significant differences between term and preterm controls (Figure 3A), in any 10 
analyzed mitochondrial region. 11 
Both cases and controls displayed low percentages of methylated cytosines (Figure 3B), pointing 12 
out a shared hypomethylation pattern in all cord blood samples (D-loop: 0.55-10.75 %; mt-CO1: 1-13 
8.5 %; mt-TF/RNR1: 0-14.75 %). Moreover, D-loop methylation levels were significantly decreased 14 
in PE/IUGR compared to controls (p=0.04; Figure 3B). Supplementary Figure 1 shows D-loop 15 
methylation levels of each investigated CpG for cases and controls. 16 
We then re-analyzed D-loop data after classifying pathologic cases according to their severity. The 17 
most severe cases, both in IUGR and in PE, displayed a significant reduction of D-loop methylation 18 
compared to controls (Figure 4), even greater than what observed for the PE/IUGR group versus 19 
controls (Figure 3B). Conversely, mild IUGR and PE samples did not show significant differences. 20 
 21 
D-loop, mt-CO1 and mt-TF/RNR1 methylation levels displayed a significant positive correlation 22 
with each other (Supplementary Figure 2). 23 
Methylated cytosines (%) in D-loop region were significantly related to umbilical vein oxygen 24 
partial pressure (pO2; Figure 5A). A significant relationship was also observed between D-loop 25 
methylation and both gestational age and fetal weight (Figures 5B and 5C). 26 
 10
Finally, we found a significant and inverse correlation between mt-CO1 methylation levels and 1 
mtDNA content, both in pathologic samples (r=-0.431, p=0.014; data not shown) and in the whole 2 
population (r=-0.369, p=0.006; Figure 5D). 3 
 4 
DISCUSSION 5 
Here we analyzed the mitochondrial DNA amount in fetal blood from pregnancies characterized by 6 
IUGR or preeclampsia compared to control pregnancies. We found significantly higher mtDNA 7 
levels in all pathologic groups than in controls, which included also preterm pregnancies with 8 
gestational age similar to cases. These results are consistent with a previous study comparing cord 9 
blood mtDNA in monochorionic twins with one IUGR fetus, that reported higher mtDNA amount 10 
in the IUGR fetuses than in their respective larger twins [31]. Moreover, our findings give novel 11 
insights into preeclamptic pregnancies, being to our knowledge the first mtDNA data in PE cord 12 
blood to be described. 13 
We previously reported that mtDNA levels, accounting for mitochondrial content, are increased in 14 
IUGR placental tissue and placental mesenchymal stromal cells but decreased in cytotrophoblast 15 
cells, compared to controls, suggesting different mitochondrial contents depending on the analyzed 16 
cell lineages [12,13,32]. A different cell composition may indeed account for the lower mtDNA 17 
amount conversely found in IUGR placentas in another study [14]. Increased mtDNA levels were 18 
also reported in blood of women with IUGR [16] and PE [17] pregnancies. 19 
Our present results suggest that fetuses react to placental insufficiency and to the adverse 20 
intrauterine environment by increasing their mitochondrial content, with a compensatory 21 
mechanism facing the oxidative stress and/or hypoxia and calorie restriction occurring in 22 
pathologies related to placental insufficiency [33,1]. In particular, IUGR fetuses are characterized 23 
by oxygen and nutrient restriction, which is known to induce mitochondrial biogenesis [34]. 24 
Preeclamptic pregnancies are instead characterized by increased oxidative stress, reported in 25 
 11
placenta, mothers and fetuses [35-36] where it might damage mitochondria, thus inducing their 1 
biogenesis. 2 
 3 
Given the recent demonstration of mitochondrial DNA methylation [18] and the known impact of 4 
adverse intrauterine conditions on epigenetic modifications, we analyzed methylation of important 5 
mitochondrial genes in cord blood of fetuses grown in an impaired environment. We focused on 6 
three mitochondrial loci, relevant to mtDNA and mitochondrial functionality. 7 
The first result of our analysis is the common hypomethylation pattern shared by all cord blood 8 
samples (controls and pathologic pregnancies), with percentages of methylated cytosines below 9 
15%. Low methylation levels had already been reported for two of these loci, D-loop (mean %: 4.0) 10 
and mt-RNR1 (mean %: 11.7), in cord blood of fetuses from the ENVIRONAGE birth cohort, which 11 
includes a very heterogeneous population but predominantly composed by normal pregnancies with 12 
vaginal deliveries [37]. This study [37] also reports a wide variability for mt-RNR1 methylation, 13 
similar to our mt-TF/RNR1 methylation data in control samples, which could however be partially 14 
explained by assay sensitivity. The observed hypomethylation, making mtDNA accessible to 15 
replication and transcription with the potential to be expressed, confirms that these mitochondrial 16 
loci and their products are essential and required in any pregnancy condition. 17 
Nevertheless, we found further decreased D-loop methylation in the most severe cases, namely 18 
PE/IUGR (14 cases), early-onset PE (3 cases) and IUGR with altered umbilical artery pulsatility 19 
index (15 cases). Moreover, low D-loop methylation levels were associated to poorer fetal 20 
outcomes, as indicated by their significant positive correlation with gestational age, fetal weight and 21 
umbilical vein pO2, all reflecting fetal conditions, in pathologic cases. A similar negative 22 
association between D-loop methylation levels and disease severity was reported in colorectal 23 
cancer [21]. 24 
The D-loop region controls mtDNA replication and its hypomethylation makes it more accessible to 25 
replication machinery. Although the mild decrease we report might not be functionally meaningful, 26 
 12
we can hypothesize that it may partially explain the increased mtDNA content we found in 1 
pathologic samples. However, additional factors can mediate mitochondrial DNA replication, such 2 
as POLG DNA polymerase or helicases [38], and their alterations would probably contribute to 3 
mtDNA increase. 4 
In addition, we found a significant negative correlation between mt-CO1 methylation and mtDNA 5 
content. 6 
 7 
Limitations 8 
One possible bias for the analysis of IUGR and PE pregnancies in control/case studies is the 9 
different gestational age, as in pathologic cases delivery is frequently induced earlier to preserve 10 
fetal and maternal health. In our study we were able to include 8 preterm control pregnancies, with 11 
normal intrauterine growth and gestational age similar to cases. This type of population is very 12 
uncommon, as preterm deliveries are often associated with fetal growth-related pathologies, thus we 13 
were not able to have a larger group, and this may represent a limitation. Of note, in cord blood of 14 
preterm fetuses we did not find any significant difference compared to term controls, in either 15 
mitochondrial DNA content or methylation, nor we observed significant correlations of these 16 
molecular data with gestational age in the control population. We may thus hypothesize that both 17 
mtDNA content and methylation are independent from gestational age in our population. 18 
Mitochondrial DNA in blood derives from white blood cells (that also bear nuclear DNA), platelets, 19 
microvescicles and cell-free DNA. Since platelets and microvescicles do not contain nuclear 20 
genome, an increase in their number would be reflected in higher abundance of mtDNA in whole 21 
blood. Unfortunately, we did not have hematocrit data or platelet indices for our population, thus we 22 
cannot exclude a different blood composition in our samples. Nevertheless, newborns from PE 23 
pregnancies or weighting less than 10th centile often present lower platelet number [39-40] and 24 
increasing platelet counts were found with advancing gestational age [41]. We can thus hypothesize 25 
 13
that the increased mtDNA levels we observed were not due to higher platelet counts in pathologic 1 
cord blood, although we cannot totally exclude this limit. 2 
 3 
Conclusions 4 
In this study we describe increased mitochondrial content in fetal blood of IUGR, PE/IUGR and PE 5 
pregnancies, suggesting a fetal response to restricted nutrients and oxygen availability as well as to 6 
oxidative stress. 7 
Moreover, this is the first study to our knowledge investigating DNA methylation of important 8 
mitochondrial regions in cord blood of pregnancies with placental insufficiency. We found a 9 
common hypomethylation pattern shared by both controls and pathologic cases, indicating the 10 
relevance of these mitochondrial genes (D-loop, CO1, TF/RNR1) that need to be expressed. 11 
Future analyses, e.g. investigating mitochondrial gene expression and function, are needed to 12 
further explore these hypotheses and to identify the relative contributions of cord blood cells or cell-13 
free DNA to the observed results. 14 
 15 
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TERM 
CONTROLS 
PRETERM 
CONTROLS IUGR PE/IUGR PE 
 (n = 35) (n = 8) (n = 31) (n = 17) (n = 17) 
   
 
 
 
 
 
 
 
Maternal age, 
years 
34 
(19-39) 
36 
(27-40) 
 35 
(22-45) 
 
36 
(33-43) 
* 37 
(17-44) 
 
Pre-pregnancy 
BMI, kg/m2 
21.2 
(18.7-25.2) 
20.2 
(19.3-31.3) 
 20.2 
(17.2-32.1) 
 
23.2 
(17.5-37.7) 
* 22.8 
(18-35.6) 
* 
 
  
 
 
 
 
 
 
 
Gestational age, 
weeks 
39.0 
(37.6-40) 
36.0 
(31.7-37) 
*** 35.9 
(28.4-39.7) 
*** 33 
(26.7-37.4) 
*** 
+
 
34.6 
(27.7-38.9) 
*** 
Fetal weight  
(F), g 
3200 
(2630-3920) 
2745 
(2580-3300) 
** 1820 
(500-2620) 
*** 
+++
 
 
1230 
(660-2250) 
*** 
+++
 2020 
(800-3170) 
*** 
+
 
Placental weight 
(P), g 
670 
(415-950) 
600 
(520-750) 
 273 
(120-580) 
*** 
+++
 
 
215 
(113-378) 
*** 
+++
 350 
(135-700) 
*** 
++
 
F/P weight ratio 4.84 (3.37-6.63) 
4.62 
(3.49-5.31) 
 5.71 
(3.32-10.75) 
* 
 
5.56 
(3.3-12.3) 
 5.52 
(2.43-9.45) 
 
 1 
 2 
Table 1. Maternal, fetal and placental data of cases and controls. Data are presented as median and range. BMI: Body Mass Index. *p<0.05, 3 
**p<0.01, ***p<0.001 versus term controls; +p<0.05, ++p<0.01, +++p<0.001 versus preterm controls. 4 
 5 
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 1 
Gene Position in 
the mtDNA 
PCR primers 5’  3’ Amplicon size / 
Annealing 
Temperature  
Pyrosequencing primers  
5’  3’ 
Sequence to analyze 
TF/RNR1  597 – 765 F: 
TAAAGTAATATATT
GAAAATGTTTAGA 
R(bio): 
TACTTAATACTTAT
CCCTTTTAATC 
168 bp / 52°C Seq1: 
TATTGAAAATGTTTAGA 
Seq2: 
GATTATATATGTAAGTA
TTT 
Seq1:  
YGGGTTTATATT 
Seq2: 
TYGTTTTAGTGAGTTTATTTTTTA
AATTATTAYGA 
D-loop 6 – 259 F: 
TGTGTAGATATTTA
ATTGTTATTATTA 
R(bio): 
CAAATCTATCACCC
TATTAACCAC 
253 bp / 54°C Seq1: 
TATTTTAGTAAGTATGT 
Seq2: 
TATTGTGATATAGGGT 
Seq1: 
TYGTTTGTAATATTGAATGTAGG
TGYGAT 
Seq2: 
GTTTYGGTTTTAGYGTTTYGTAA
TGTTATYGYGTGTAT 
CO1 5882 – 5999 F(bio): 
TATTTTATTTTATTT
TTATTGATGT 
R: 
AACTATACCTAAAA
CTCCAACTCA 
117 bp / 54°C TAAAACTCCAACTCATA CRCCRAATAATAAATATAATATT
CCAATATCTTTATAATTTATAAA
AAATAATCAACRATCRACRA 
 2 
Supplementary Table. PCR and pyrosequencing primers and conditions. F: forward, R: reverse, (bio): biotin-labeled. Analyzed CpGs are 3 
underlined. 4 
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FIGURES 1 
 2 
Figure 1: mtDNA levels in cord blood of (A) term and preterm controls, (B) control 3 
(term+preterm), IUGR, PE/IUGR and PE pregnancies. Medians and significant p values versus 4 
controls are displayed. mtDNA content was calculated as 2-∆Cq, where ∆Cq = Cytochrome B (mt 5 
gene) Cq – RNase P (nuclear gene) Cq. 6 
 7 
 8 
Figure 2: mtDNA content in 9 
pathologic samples divided 10 
according to severity. Medians and 11 
significant p values versus controls 12 
are displayed. mtDNA content was 13 
calculated as 2-∆Cq, where ∆Cq = 14 
Cytochrome B (mt gene) Cq – 15 
RNase P (nuclear gene) Cq. 16 
 17 
 17
 1 
Figure 3: Methylated cytosine percentages in D-loop, CO1, and TF/RNR1 mitochondrial regions. 2 
Cord blood samples from (A) term and preterm controls, (B) control (term+preterm), IUGR, 3 
PE/IUGR and PE pregnancies. Medians and significant p values versus controls are displayed.  4 
 18
1 
Supplementary Figure 1 2 
 3 
 4 
Figure 4: D-loop methylated cytosine percentages in pathologic samples divided according to 5 
severity. Medians and significant p values versus controls are displayed.  6 
 19
1 
Figure 5: Correlations between molecular and clinical data.  2 
Correlation between D-loop methylation and (A) umbilical vein oxygen partial pressure (r=0.457, 3 
p=0.011), (B) gestational age (r=0.378, p=0.013), and (C) fetal weight (r=0.385, p=0.008), in 4 
pathologic pregnancies. pO2: oxygen partial pressure; : IUGR, : PE/IUGR, : PE.  5 
(D): Correlation between mtDNA content and mt-CO1 methylation (both natural logarithm 6 
transformed) in the whole population (r=-0.369, p=0.006). : controls, : IUGR, : PE/IUGR, 7 
: PE. 8 
 9 
 20
 1 
Supplementary Figure 2 2 
3 
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